Eris Lifesciences Revenue and Competitors

Ahmedabad, India



Total Funding



Estimated Revenue & Valuation

  • Eris Lifesciences's estimated annual revenue is currently $56.6M per year.(i)
  • Eris Lifesciences's estimated revenue per employee is $100,500

Employee Data

  • Eris Lifesciences has 563 Employees.(i)
  • Eris Lifesciences grew their employee count by 21% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

The journey of Eris Lifesciences began in 2007, focusing on the chronic drug segments of cardiology and diabetes. This Ahmedabad based emerging pharmaceutical major now ranks among the top 25 pharmaceutical companies in the Indian Pharmaceutical Market (IPM). In 2017, Eris made a public offer of its shares and is listed on the Bombay Stock Exchange (Code: 540596) and National Stock Exchange (Code: ERIS). Eris derives 66% of its revenues from the chronic segment, where it ranks among the top 20 players in the cardio and anti-diabetes therapeutic groups in the IPM. Recently, Eris forayed into the Central Nervous System (CNS) category, strengthening its presence in the top three chronic segments. The Company also has the biggest market share for the Vitamin D product. The genesis of Eris was rooted in the understanding of healthcare delivery gaps in an emerging country like India. Realizing the challenges of poor diagnosis, poor patient compliance, population-provider burden, etc. and the limitations of a single company to address these challenges, Eris adopted a partnering mindset and approach by aligning with like-minded institutions and adopting innovative programmes for engagement. Eris Lifesciences is a young company which imbibes qualities of youth - imagination, courage and passion.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Eris Lifesciences News

2022-04-17 - Are newly diagnosed type 2 diabetes patients at risk of developing some form of cardiovascular disease?

Co-authored by 16 doctors between 2020-2021, the study was conducted in partnership with over 1,900 physicians by Eris Lifesciences with a...

2022-04-13 - Eris Lifesciences Q4 PAT seen up 30.7% YoY to Rs 89.2 cr: Prabhudas Lilladher

Net Sales are expected to increase by 12.2 percent Y-o-Y (down 6.1 percent Q-o-Q) to Rs 312.1 crore, according to Prabhudas Lilladher. ... Eris...

2022-03-30 - Investors one-year returns in Eris Lifesciences (NSE:ERIS) have grown faster than the company's underlying earnings growth

Investors one-year returns in Eris Lifesciences (NSE:ERIS) have grown faster than the company's underlying earnings growth. By: Simply Wall St.

2019-09-08 - Volatility 101: Should Eris Lifesciences (NSE:ERIS) Shares Have Dropped 40%?

Unfortunately the Eris Lifesciences Limited (NSE:ERIS) share price slid 40% over twelve months. That contrasts poorly with the market return of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding